On April 21, 2026, Vietnam Medical Pharmaceutical Investment Joint Stock Company (VMPI) successfully held its 2026 Annual General Meeting of Shareholders at the 8th Floor Hall, VNCC Building, No. 243 De La Thanh Street, Lang Ward, Hanoi. 

The meeting was attended by the Board of Directors, the Executive Board, and shareholders, marking an important milestone in VMPI’s development journey and strategic direction.

Strengthening Internal Capabilities through Culture and Governance

At the meeting, the Board of Management presented the 2025 performance review and the 2026 development plan, highlighting positive improvements in corporate governance. The year 2025 marked four years since VMPI implemented the OKRs management approach. This system has now been effectively and consistently applied, enhancing transparency and fostering a proactive mindset across the organization.

In parallel, VMPI continues to strengthen and develop its corporate culture towards professionalism, continuous learning, and cohesion. The spirit of internal training has been widely promoted, contributing to improved team capabilities while shaping a VMPI workforce that is cheerful, friendly, and collaborative—key elements of a positive and sustainable working environment. Notably, the official implementation of the “3Ts Culture” (Customer-Centricity – Lean & High Performance – Speed & Determination) has established a shared behavioral framework, enhancing consistency in management and internal coordination. This serves as a solid foundation for optimizing operational efficiency and strengthening execution capabilities in the next phase of development.

2026 Strategy: Centralized Governance – Strength Through Alignment

Entering 2026, VMPI has defined its guiding principle as “Adaptability, Sustainability, and Speed.” The most significant governance innovation this year is the direct and comprehensive executive role of the Chairman of the Board of Directors.

Under the close and hands-on direction of the Chairman, all company operations will be aligned along a unified axis. This model is designed to ensure that decisions are made swiftly, decisively, and accurately. Such centralized governance not only optimizes processes but also builds strong trust and absolute alignment—from leadership to every employee—empowering the entire organization to confidently contribute to shared goals.

Expansion and Specialized Development Plans

Based on strong alignment in governance, VMPI will focus on key strategic priorities:

• Positioning business operations as the core driver of growth, with a focus on high-tech, specialized products and innovative solutions in both medical devices and consumables.
• Leveraging its existing strengths in neurointervention and its newly expanded capabilities in cardiovascular intervention, the Company will continue to seek products and solutions related to interventional fields in general.
• Expanding research into anti-aging products and solutions, a sector expected to be a major trend in the future.

The 2026 Annual General Meeting of Shareholders concluded successfully. With a centralized and consistent governance model, along with strong unity across all employees, VMPI is confident in its solid foundation to accelerate growth, expand market coverage, and reinforce its leading position in the medical device industry.